相关实验视频

Updated: Jun 14, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

内在的ADRB2抑制改善了CAR-T细胞治疗对前列腺癌的疗效

Iqra Ajmal¹, Muhammad Asad Farooq¹, Yixin Duan¹

¹Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, China.

Molecular therapy : the journal of the American Society of Gene Therapy

|September 4, 2024

概括

研究人员通过降低T细胞中腺核受体β-2 (ADRB2) 的下调来增强了仿真抗原受体 (CAR) -T细胞疗法. 这种修改改善了对固体瘤的抗瘤活性,为癌症治疗提供了有前途的新策略.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
细胞疗法细胞疗法

背景情况:

化学抗原受体 (CAR) -T细胞疗法在固体瘤中显示出有限的疗效.
腺体受体β-2 (ADRB2) 作为一种新的检查点受体,抑制T细胞抗瘤反应.
向瘤微环境中的上腺体信号是一种潜在的治疗策略.

研究的目的:

研究ADRB2在CAR-T细胞功能中的作用.
通过降低ADRB2 (shβ2-CAR-T) 的调节来开发增强的CAR-T细胞.
评估shβ2-CAR-T细胞对前列腺癌的疗效.

主要方法:

用RNA干扰来降低CAR-T细胞中的ADRB2的调节.
在体外测试中评估了CAR-T细胞的细胞毒性,增殖,亡和免疫标记物表达.
在携带瘤的小鼠体内研究比较shβ2-CAR-T细胞与传统的CAR-T细胞.

主要成果:

在ADRB2 Knockdown CAR-T细胞中,细胞毒性和效应因子功能增强 (增加CD69,CD107a,GzmB,IFN-γ,T-bet,GLUT-1).
ADRB2缺乏改善了CAR-T细胞增殖,增加了CD8/CD4T细胞比率,减少了细胞亡,并促进了中央记忆细胞的产生.
与传统的CAR-T细胞相比,shβ2-CAR-T细胞在体内表现出优异的瘤根除能力.
确定ZAP-70/NF-κB信号通路对于增强功能至关重要.

结论:

降低ADRB2的调节显著增强了CAR-T细胞对固体瘤的抗瘤活性.
向ADRB2代表了一种新的方法来克服瘤微环境中的T细胞耗尽.
这一策略有可能在未来用于癌症CAR-T细胞治疗的临床应用.

关键词:

在ADRB2中,它是ADRB2.汽车汽车汽车汽车在CAR-T细胞疗法中.上腺应激的压力上腺受体β-2 的作用.仿制性抗原受体的复制性受体.组合疗法治疗组合治疗.免疫检查点是一个检查点.免疫疗法免疫疗法神经免疫学神经免疫学前列腺癌是前列腺癌.瘤微环境是一个微环境.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...